Wellington Management Group LLP Sells 8,590 Shares of CareDx, Inc (NASDAQ:CDNA)

Wellington Management Group LLP trimmed its position in shares of CareDx, Inc (NASDAQ:CDNA) by 4.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 193,722 shares of the company’s stock after selling 8,590 shares during the period. Wellington Management Group LLP owned about 0.36% of CareDx worth $6,049,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CDNA. Renaissance Technologies LLC grew its stake in shares of CareDx by 6.2% during the second quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company’s stock valued at $23,492,000 after buying an additional 88,100 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in CareDx by 868.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company’s stock valued at $6,401,000 after acquiring an additional 183,823 shares during the last quarter. Driehaus Capital Management LLC purchased a new stake in CareDx in the second quarter worth $2,852,000. Hanseatic Management Services Inc. purchased a new stake in CareDx in the third quarter worth $781,000. Finally, Creative Planning bought a new stake in shares of CareDx during the third quarter worth $204,000.

CareDx Stock Up 0.0 %

Shares of NASDAQ:CDNA opened at $22.87 on Tuesday. The firm has a 50 day moving average of $24.48 and a 200 day moving average of $23.24. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -8.47 and a beta of 1.84. CareDx, Inc has a 52 week low of $7.42 and a 52 week high of $34.84.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $82.88 million during the quarter, compared to analysts’ expectations of $80.04 million. During the same period in the prior year, the business posted ($0.43) EPS. The firm’s quarterly revenue was up 23.4% on a year-over-year basis. On average, sell-side analysts expect that CareDx, Inc will post -0.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on CDNA shares. Wells Fargo & Company started coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target on the stock. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. The Goldman Sachs Group lifted their price target on shares of CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. BTIG Research dropped their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.60.

Insider Transactions at CareDx

In related news, Director Peter Maag sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the director now directly owns 330,024 shares in the company, valued at $8,250,600. The trade was a 1.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.90% of the company’s stock.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.